Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

62462 1502285060HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

Study: Subbing Avastin for Lucentis could save U.S. $3B on eye treatment

03.06.2014 / Fierce Pharma

Doctors have long repurposed Roche's Avastin for the eye in place of using the company's pricier Lucentis to save money. Now, a study says the U.S. could save almost $3 billion a year if Medicare patients received the cheaper drug–a prospect Roche isn't so keen on.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: